Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622), has seen a significant stock price increase of over 35% this week, with a current price of HKD 3.78 and a trading volume of HKD 22.5882 million, following the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Group 1: Product Development - The TONO-i device will be a crucial part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - TONO-i provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, which aids in delivering immediate and continuous feedback on treatment efficacy, thereby improving patient compliance with glaucoma medication [1] - The introduction of TONO-i into the company's pipeline signifies its commitment to a dual approach in glaucoma management, focusing on both treatment and diagnosis [1] Group 2: Distribution Agreement - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of developing diagnostic, therapeutic, and preventive medical devices for glaucoma [1] - Under the terms of the agreement, the company holds exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which were later expanded to include Thailand and Malaysia, effective from August 2024 [1]
兆科眼科-B再涨超7% 本周累涨近35% TONO-i眼压计获颁医疗器械注册证书